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OBJECTIVES: To estimate the direct costs of maintaining
normal sinus rhythm (NSR) in patients with atrial fibrilla-
tion (AF) with four antiarrhythmic (AA) drugs (sotalol,
amiodarone, flecainide, and propafenone) in the Nether-
lands (NL).
METHODS: A Markov model, with a one month cycle
length and a one year treatment duration, was used to esti-
mate expected costs of maintaining NSR. An expert panel
of cardiologists was interviewed to collect data on the per-
ceived safety and efficacy of the drugs, resource use (inpa-
tient and outpatient visits, tests and procedures) for recur-
rence of AF, treatment initiation, monitoring, and side
effects. Cost data were obtained principally from the Cen-
tral Organization for Tariffs in Health Care and the Na-
tional Association of Pharmacists. Costs were estimated
separately by drugs and for patients with and without con-
comitant structural heart disease (SHD), then weighted by
the joint distribution of presence or absence of SHD, spe-
cific use of a drug in these two populations, and/or market
share of AA drugs.
RESULTS: The weighted average annual cost of maintain-
ing NSR in an AF patient was US$2,181.31. Inpatient
treatment costs, dominated mainly by costs of symptom
recurrence and therapy initiation, ranged from 78%
(flecainide) to 92% (sotalol) of total costs. Costs of moni-
toring and side effects were the highest for amiodarone
and sotalol, respectively. Drug costs, ranging from $60 for
sotalol to $252 for flecainide, were the minor contributors
to the total costs. In patients with SHD, annual costs of
maintaining NSR were $2,685 and $2,505 for sotalol and
amiodarone, the two most common drugs in the NL, re-
spectively.
CONCLUSIONS: The estimated annual cost of maintain-
ing NSR in patients with AF in the NL is as high as
US$2,685 per patient. Relatively lower AA drug costs are
offset by significant medical treatment costs, particularly
for inpatient therapy initiation and recurrence of disease
symptoms.
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OBJECTIVES: No studies to date have addressed the cost-
effectiveness of lifelong dietary treatment when adminis-
tered in “real world” community practice. This study ex-
amines whether a comprehensive intervention program to
detect and treat, through dietary therapy, hypercholester-
olemic patients is a cost-effective approach in the primary
prevention of morbidity and mortality from coronary
heart disease (CHD).
METHODS: I developed a multidimensional model of
CHD incidence using results from the Physician-Assisted
Cholesterol Education Program (PACE), a prospective
randomized trial in rural clinical practice, in combination
with multivariate logistic risk functions from the Framing-
ham Heart Study. The cost and health effects of this di-
etary intervention are projected over a lifetime for patients
with known CHD risk factors. Results were also simulated
for the pharmacologic treatment of lovastatin taken daily
in addition to dietary intervention. Changes in life expect-
ancy, quality-adjusted life expectancy, and incremental
cost-effectiveness ratios ($/QALY), were the primary out-
come measures of interest.
RESULTS: PACE participants, on average, reduced their
total serum cholesterol levels 1.3% (CI 0.43–2.14). Rela-
tive to no treatment, men on dietary treatment gained an
estimated 4 to 26 days of quality-adjusted life expectancy
at an estimated cost-effectiveness of $14,463 to $77,574
($/QALY), depending on the age of treatment initiation.
Women gained an estimated 3 to 19 days with cost-effec-
tiveness ratios from $49,998 to $102,574 ($/QALY). Rel-
ative to dietary treatment alone, the cost-effectiveness of
the combined diet-plus-lovastatin treatment ranged from
$43,620 to $49,776 ($/QALY) in men, and from $52,996
to $74,718 ($/QALY) in women.
CONCLUSIONS: Dietary intervention is a relatively cost-
effective method of CHD prevention and should remain
the preferred treatment option for younger men and
women—especially for those initially at highest risk of
CHD. Combined diet-plus-lovastatin therapy, however, is
the optimal treatment choice for older individuals and for
those who experience a reduced quality of life on stringent
dietary regimes.
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OBJECTIVES: The objective of the study was to estimate
the direct costs of maintaining normal sinus rhythm (NSR)
in patients with atrial fibrillation or flutter (AF/F) with five
antiarrhythmic (AA) agents (amiodarone, flecainide, pro-
pafenone, quinidine, sotalol).
METHODS: A Markov model was used to estimate the
expected costs of maintaining NSR in patients with AF/F
using AA therapies. Estimates of the resource utilization
(inpatient therapy initiation and monitoring, recurrence,
